

Regimen Monograph

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication and Supportive Measures](#) | [Administrative Information](#) | [References](#) | [Other Notes](#) | [Disclaimer](#)

A - Regimen Name

GCVP+RITU Regimen

Gemcitabine - Cyclophosphamide - VinCRISTine - Prednisone - Rituximab**Disease Site** Hematologic - Lymphoma - Non-Hodgkin's High Grade**Intent** Curative**Regimen Category** **Evidence-informed :**

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

This **Regimen Abstract** is an **abbreviated** version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Rationale and Uses For use in DLBCL when anthracycline is contraindicated.**Supplementary Public Funding** **prednisone**
ODB - General Benefit (prednisone) ([ODB Formulary](#))**[riTUXimab \(subcut\)](#)**

New Drug Funding Program (Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma)

riTUXimab

New Drug Funding Program (Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma)

[back to top](#)

B - Drug Regimen

Note: Different rituximab products are NOT INTERCHANGEABLE.

Cycle 1: All patients must receive their first dose of rituximab by IV infusion.

riTUXimab	375 mg /m ²	IV	Day 1
gemcitabine	750 - 1000 mg /m ²	IV	Days 1 and 8
cyclophosphamide	750 mg /m ²	IV	Day 1
vinCRISTine	1.4 mg /m ²	IV (max 2 mg)	Day 1
prednisone*	100 mg	PO daily	Days 1 to 5

(Outpatient prescription in multiples of 50mg tablets)

Cycle 2 and onwards [up to 6 cycles in total, including initial IV rituximab cycle(s)]:

Rituximab IV:

riTUXimab	375 mg /m ²	IV	Day 1
---------------------------	------------------------	----	-------

OR

Rituximab (subcut):

The subcutaneous formulation must only be given at the second or subsequent cycles, if the patient has previously received at least one full rituximab IV dose.

riTUXimab (subcut)	1400 mg	Subcut	Day 1
------------------------------------	---------	--------	-------

Plus GCVP chemotherapy:

gemcitabine	750 - 1000 mg /m ²	IV	Days 1 and 8
cyclophosphamide	750 mg /m ²	IV	Day 1
vinCRIS^tine	1.4 mg /m ²	IV (max 2 mg)	Day 1
prednisone*	100 mg	PO daily	Days 1 to 5

(Outpatient prescription in multiples of 50mg tablets)

*On Day 1 to be given as part of premedication before ritUXimab

[back to top](#)

C - Cycle Frequency**REPEAT EVERY 21 DAYS**

For a usual total of 6 cycles unless disease progression or unacceptable toxicity occurs

[back to top](#)

D - Premedication and Supportive Measures

Antiemetic Regimen: Moderate (D1)
Low (D8)

Febrile Neutropenia Risk: High
Consider G-CSF prophylaxis for patients at high risk of febrile neutropenia. See [G-CSF recommendations](#).

Other Supportive Care:

Also refer to [CCO Antiemetic Recommendations](#).

[back to top](#)

J - Administrative Information

Approximate Patient Visit	Day 1 - First cycle: 6.5 hours; subsequent cycles: 2 to 5 hours; Day 8: 0.5 hour
Pharmacy Workload (average time per visit)	37.897 minutes
Nursing Workload (average time per visit)	63.25 minutes

[back to top](#)

K - References

Fields PA, Townsend W, Webb A et al. De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial. *J Clin Oncology* 2014; 32:282-287.

Lugtenburg P, Avivi I, Berenschot H et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. *Haematologica*. 2017;102(11):1913-1922.

Rummel M, Kim TM, Aversa F et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). *Ann Oncol*. 2017;28(4):836-842.

PEBC Advice Documents or Guidelines

- [Rituximab in Lymphoma and Chronic Lymphocytic Leukemia](#)

August 2020 Updated NDFP forms and interchangeability information in Drug Regimen sections

[back to top](#)

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all

uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the “Formulary”) is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.

[back to top](#)